Agenus Inc. [NASDAQ: AGEN] gained 3.33% or 0.09 points to close at $2.79 with a heavy trading volume of 3840385 shares. The company report on June 30, 2022 that Agenus to Participate at William Blair’s Biotech Focus Conference.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chief Medical Officer, will participate in a panel discussion on developing therapies for the next immuno-oncology targets at William Blair’s Biotech Focus Conference on Tuesday, July 12, 2022, at 4:10 PM EST.
The Conference will be held at The St. Regis New York hotel from July 12th – 13th, during which Agenus will also host one-on-one meetings with investors.
It opened the trading session at $2.75, the shares rose to $2.87 and dropped to $2.64, the range by which the price of stock traded the whole day. The daily chart for AGEN points out that the company has recorded -8.52% loss over the past six months. However, it is still -123.2% lower than its most recent low trading price.
If we look at the average trading volume of 5.04M shares, AGEN reached to a volume of 3840385 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Agenus Inc. [AGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGEN shares is $9.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGEN stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 16, 2021. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on November 19, 2019, representing the official price target for Agenus Inc. stock. On October 28, 2016, analysts decreased their price target for AGEN shares from 10 to 5.
The Average True Range (ATR) for Agenus Inc. is set at 0.23, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 2.42. The Price to Book ratio for the last quarter was 46.50, with the Price to Cash per share for the same quarter was set at 0.98.
Trading performance analysis for AGEN stock
Agenus Inc. [AGEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.57. With this latest performance, AGEN shares gained by 99.29% in over the last four-week period, additionally sinking by -8.52% over the last 6 months – not to mention a drop of -48.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 67.80, with the RSI for the last a single of trading hit 67.94, and the three-weeks RSI is set at 65.45 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 1.86, while it was recorded at 2.83 for the last single week of trading, and 2.87 for the last 200 days.
Agenus Inc. [AGEN]: A deeper dive into fundamental analysis
Agenus Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.80.
An analysis of insider ownership at Agenus Inc. [AGEN]
There are presently around $367 million, or 51.40% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: VANGUARD GROUP INC with ownership of 18,402,409, which is approximately 4.354% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 17,955,622 shares of the stock with an approximate value of $48.48 million in AGEN stocks shares; and STATE STREET CORP, currently with $47.95 million in AGEN stock with ownership of nearly -16.118% of the company’s market capitalization.
80 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 22,911,400 shares. Additionally, 83 investors decreased positions by around 21,517,777 shares, while 39 investors held positions by with 91,362,748 shares. The mentioned changes placed institutional holdings at 135,791,925 shares, according to the latest SEC report filing. AGEN stock had 26 new institutional investments in for a total of 16,294,988 shares, while 33 institutional investors sold positions of 5,345,608 shares during the same period.